Archives: 2026-08-19

PIER MARIA FORNASARI
2026-08-19

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The Companies plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions for intismeran autogene in combination with

Read More

No Comments InCANCER IMMUNOTHERAPY PRECISION MEDICINE
PIER MARIA FORNASARI
2026-08-18

Implantable device may help restore function after spinal cord injury

Ultra thin, flexible interface locates alternative signal pathways to bypass affected area Researchers from Houston Methodist and the University of Cambridge have developed a flexible device that wraps around the spinal cord and can simultaneously interpret multiple signals related to movement, sensation and internal body functions. The research demonstrates that a single device may be

Read More

No Comments InRESEARCH
PIER MARIA FORNASARI
2026-08-18

Researchers find cold-stored platelets safe and effective in cardiac surgery up to 21 days

CHIP trial extends shelf life compared with conventional room-temperature storage Key Takeaways Extending the shelf life of platelets with refrigeration didn’t hurt their hemostatic function for people undergoing complex cardiac surgery, the landmark CHIPS trial found. Platelets stored at 1-6°C (33.8-42.8°F) for up to 21 days were noninferior to platelets stored up to 7 days

Read More

No Comments InCLINICAL TRIALS
PIER MARIA FORNASARI
2026-08-17

Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO new GLP 1 Consensus Statement.

The Lancet Diabetes & Endocrinology recently published a consensus piece on using GLP-1 medications for obesity in Europe. The paper, “Nutritional, Functional, and Psychological Considerations for Incretin-Based Therapies in Adults—an EASO, EFAD, and ECPO Consensus Statement“, aimed to provide guidance on best practices for clinicians prescribing obesity medications — but one could argue, it’s more likely to lead

Read More

No Comments InWELLNESS